← Russell 3000 cross-section

HRMY Harmony Biosciences Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$2.3bn
Revenue TTM
$960m
Net income TTM
$181m
Free cash flow
Composite score
83.4
Sector rank
#1557

Valuation

P / E
12.8
EV / EBITDA
EV / sales
1.9
FCF yield
Earnings yield vs 10-yr
3.11pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
18.9%
EBITDA margin
ROE
18.1%
ROIC
49.6%
Revenue growth
24.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Cost of Product Sold Cost of product sold includes manufacturing and distribution costs, the cost of API, FDA program fees, royalties due to third parties on net product sales, freight, shipping, handling, storage costs, and salaries of employees involved with oversight of production. Product candidates in later stages of clinical development generally have higher development costs in the current period than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, milestone payments, and the cost of submitting an NDA to the FDA (and/or other regulatory authorities). …Harmony Biosciences Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →